Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

26.60
+1.516.02%
Post-market: 26.680.0800+0.30%17:56 EDT
Volume:1.16M
Turnover:30.15M
Market Cap:3.00B
PE:-17.21
High:26.86
Open:24.82
Low:24.81
Close:25.09
52wk High:27.29
52wk Low:14.06
Shares:112.63M
Float Shares:64.72M
Volume Ratio:0.99
T/O Rate:1.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5455
EPS(LYR):-2.5604
ROE:-28.43%
ROA:-17.12%
PB:3.85
PE(LYR):-10.39

Loading ...

NewAmsterdam Pharma Announces Amended Employment Agreement for Chief Scientific Officer Dr. John Kastelein

Reuters
·
Jul 12

NewAmsterdam Pharma Company NV Publishes Document on Obicetrapib's Impact on LDL-Cholesterol Clearance Rates

Reuters
·
Jul 03

Director James N. Topper Reports Acquisition of Common Shares in NewAmsterdam Pharma Company NV

Reuters
·
Jun 27

Director James N. Topper Reports Acquisition of Common Shares in NewAmsterdam Pharma Company NV

Reuters
·
Jun 19

NewAmsterdam Pharma Initiated at Buy by Citigroup

Dow Jones
·
Jun 17

NewAmsterdam Pharma Price Target Maintained With a $40.00/Share by Needham

Dow Jones
·
Jun 12

Sector Update: Health Care Stocks Steady Premarket Monday

MT Newswires Live
·
Jun 09

Top Premarket Gainers

MT Newswires Live
·
Jun 09

NewAmsterdam Pharma Announces Positive Phase 3 BROADWAY Trial Results Linking Obicetrapib to Alzheimer's Biomarker Reduction

Reuters
·
Jun 09

NewAmsterdam Pharma Company NV Conducted Annual General Meeting

Reuters
·
Jun 07

NewAmsterdam Pharma Company NV Publishes Study on Obicetrapib's Safety and Efficacy in High Cardiovascular Risk Patients

Reuters
·
Jun 06

NewAmsterdam Pharma to Host R&D Day Event in New York City

Reuters
·
Jun 05

Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target

MT Newswires Live
·
Jun 04

NewAmsterdam Pharma Company NV Files Initial Beneficial Ownership Statement for Michael F. Marino III, Officer

Reuters
·
Jun 04

NewAmsterdam Pharma Company NV Publishes Document on Safety and Efficacy of Obicetrapib for Heterozygous Familial Hypercholesterolemia

Reuters
·
May 30

NewAmsterdam Pharma Company NV Releases Study on Obicetrapib's Effects on Cholesterol Transport in Mice

Reuters
·
May 30

NewAmsterdam Pharma to Present at William Blair 45th Annual Growth Stock Conference in Chicago

Reuters
·
May 27

Douglas F. Kling, Chief Operating Officer, Reports Disposal of Common Shares of NewAmsterdam Pharma Company NV

Reuters
·
May 20

NewAmsterdam Pharma to Present at 2025 RBCCM Global Healthcare Conference

Reuters
·
May 14

Press Release: Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

Dow Jones
·
May 10